Stock Analiz

UNITED THERAPEUTICS Corp (UTHR) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

UNITED THERAPEUTICS’s revenue went from $1.6B in fiscal 2016 to $3.2B in fiscal 2025, growth of about 7.9% a year.

Net income in fiscal 2025 was $1.3B, a net margin of 41.9%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $3.2B and net income $1.2B.

Free cash flow was $1.0B in fiscal 2025 and positive in 9 of the 10 years shown.

The diluted share count rose 2% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $1.6B162017: $1.7B172018: $1.6B182019: $1.4B192020: $1.5B202021: $1.7B212022: $1.9B222023: $2.3B232024: $2.9B242025: $3.2B25$3.2B
Net income
2016: $714M162017: $418M172018: $589M182019: -$104M192020: $515M202021: $476M212022: $727M222023: $985M232024: $1.2B242025: $1.3B25$1.3B
Free cash flow
2016: $606M162017: $388M172018: $594M182019: -$290M192020: $696M202021: $477M212022: $664M222023: $748M232024: $1.1B242025: $1.0B25$1.0B
EPS (diluted)
2016: $15.25162017: $9.31172018: $13.39182019: $-2.39192020: $11.54202021: $10.06212022: $15.00222023: $19.81232024: $24.64242025: $27.8625$27.86

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3.2B$3.2B$2.9B$2.3B$1.9B$1.7B$1.5B$1.4B$1.6B$1.7B$1.6B
Gross profit$2.8B$2.8B$2.6B$2.1B$1.8B$1.6B$1.4B$1.3B$1.4B$1.6B$1.5B
Operating income$1.3B$1.5B$1.4B$1.2B$980M$556M$594M-$188M$805M$815M$1.1B
Net income$1.2B$1.3B$1.2B$985M$727M$476M$515M-$104M$589M$418M$714M
EPS (diluted)$26.49$27.86$24.64$19.81$15.00$10.06$11.54$-2.39$13.39$9.31$15.25
R&D$703M$550M$481M$408M$323M$540M$358M$1.2B$358M$265M$148M
Revenue growth—+10.6%+23.6%+20.2%+14.9%+13.6%+2.4%−11.0%−5.7%+7.9%+9.1%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$1.4B$1.6B$1.3B$978M$802M$598M$756M-$207M$778M$474M$644M
Capital spending-$562M-$520M-$246M-$230M-$139M-$121M-$59M-$84M-$184M-$86M-$38M
Free cash flow$867M$1.0B$1.1B$748M$664M$477M$696M-$290M$594M$388M$606M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$2.0B$1.0B$1.0B$0$0————$250M$500M
Stock-based pay$157M$148M$144M$39M$107M$138M$164M$45M-$26M$74M$12M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$2.9B$3.3B$3.0B$2.8B$1.9B$1.8B$1.5B$1.4B$927M$1.1B
Debt—$0$300M$700M$800M$800M$800M$855M$508M$250M—
Equity—$7.1B$6.4B$6.0B$4.8B$4.0B$3.4B$2.8B$2.8B$2.1B$1.9B
Total assets—$7.9B$7.4B$7.2B$6.0B$5.2B$4.6B$3.9B$3.4B$2.9B$2.3B
Shares (diluted)45M48M48M50M48M47M45M44M44M45M47M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin86.3%87.9%89.2%88.9%92.2%92.7%92.7%91.9%87.8%93.9%95.5%
Operating margin41.4%46.9%47.9%50.9%50.6%33.0%40.0%-13.0%49.5%47.2%66.4%
Net margin38.6%41.9%41.5%42.3%37.6%28.2%34.7%-7.2%36.2%24.2%44.6%
FCF margin27.2%32.7%37.5%32.1%34.3%28.3%46.9%-20.0%36.5%22.5%37.9%
ROIC—16.4%15.9%13.7%13.4%9.4%11.4%-3.3%19.0%18.8%38.6%
ROE—18.8%18.6%16.5%15.2%12.0%15.2%-3.8%21.1%19.9%38.6%

Frequently asked questions

What is UNITED THERAPEUTICS’s annual revenue?

$3.2B in fiscal 2025 and $3.2B over the twelve months to September 30, 2026.

How much profit does UNITED THERAPEUTICS make?

Net income was $1.3B in fiscal 2025 (net margin 41.9%).

Is UNITED THERAPEUTICS’s revenue growing?

Yes: revenue rose 10.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.